The tumor necrosis factor receptor (TNFR) ECD, the active domain in etanercept, was fused to the carboxyl terminus of each heavy chain of the high affinity bivalent TfRMAb, and mice with experimental PD were treated every other day for 3 weeks with IV injections of saline, 1 mg/kg etanercept, or 1 mg/kg of the TfRMAb-TNFR fusion protein (Zhou et al, 2011b). Here, TNFRSF1A is linked to Parkinson disease.